BRIEF-Amylyx Pharmaceuticals Q4 EPS USD -0.3 Vs. IBES Estimate USD -0.36

-1.77%

Amylyx Pharmaceuticals, Inc.

AMLX

13.85

-1.77%

Mar 03 (Reuters) - Amylyx Pharmaceuticals Q4 operating income USD -36.605 million vs. IBES estimate USD -40.4 million.

Q4 operating expenses USD 36.605 million
Q4 net income USD -32.999 million vs. IBES estimate USD -37.1 million
Q4 pretax profit USD -32.953 million vs. IBES estimate USD -39 million
Q4 cash & investments USD 317 million

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.